{"id":45378,"date":"2022-06-22T19:01:43","date_gmt":"2022-06-22T17:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/"},"modified":"2022-06-22T19:01:43","modified_gmt":"2022-06-22T17:01:43","slug":"ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/","title":{"rendered":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology"},"content":{"rendered":"
\n

\nFirst full-solution sale endorsing Ikonisys business model and <\/i><\/b>paving the way for further sales activity<\/i><\/b>\n<\/p>\n

PARIS–(BUSINESS WIRE)–Ikonisys SA <\/b>(Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the first sale of an Ikoniscope20 digital fluorescence microscope solution together with its optimized reagents.\n<\/p>\n

\nAs announced during the IPO of Ikonisys, the primary initial focus of the commercialization strategy for the United States is to convert current customers into Ikoniscope20 users. An active user of Ikonisys\u2019 former Ikoniscope Gen1 platform up to today, Comprehensive Urology has decided to upgrade its system to the Ikoniscope20 and at the same time to utilize the optimized reagents provided by Ikonisys to perform its bladder cancer molecular diagnosis.\n<\/p>\n

\nIkonisys\u2019 business model is to sell a fully integrated solution comprising hardware, software and consumables. Reagents, needed to perform each single test, are an essential part of the molecular diagnostics market. Ikonisys is offering clients optimized reagents at a competitive rate, ensuring greater performance with the ikoniscope20.\n<\/p>\n

\nThe Ikoniscope20 combined with Ikonisys\u2019 FISH probes will automate early bladder cancer diagnosis, allowing Comprehensive Urology to perform several thousand tests per year.\n<\/p>\n

\nPlease find the full press release on the investors website<\/a>.<\/b>\n<\/p>\n

\nAbout Ikonisys<\/b>\n<\/p>\n

\nIkonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20\u00ae platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).\n<\/p>\n

\nFor further information, please go to www.Ikonisys.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIkonisys<\/b>
Alessandro Mauri
\n
CFO
\n
investors@ikonisys.com<\/a>\n<\/p>\n

\nNewCap<\/b>
Olivier Bricaud \/ Louis-Victor Delouvrier
\n
Investor Relations
\n
Ikonisys@newcap.eu<\/a>
Tel.: +33 (0)1 44 71 94 92\n<\/p>\n

\nNewCap<\/b>
Nicolas Merigeau
\n
Media Relations
\n
Ikonisys@newcap.eu<\/a>
Tel.: <\/b>+33 (0)1 44 71 94 98\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

First full-solution sale endorsing Ikonisys business model and paving the way for further sales activity PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the first sale of an Ikoniscope20 digital fluorescence microscope … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45378","6":"format-standard","7":"category-industry"},"yoast_head":"\nIkonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First full-solution sale endorsing Ikonisys business model and paving the way for further sales activity PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the first sale of an Ikoniscope20 digital fluorescence microscope ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T17:01:43+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology\",\"datePublished\":\"2022-06-22T17:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/\"},\"wordCount\":371,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/\",\"name\":\"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-06-22T17:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/","og_locale":"en_US","og_type":"article","og_title":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend","og_description":"First full-solution sale endorsing Ikonisys business model and paving the way for further sales activity PARIS–(BUSINESS WIRE)–Ikonisys SA (Code ISIN: FR00140048X2 \/ Mn\u00e9monique: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the first sale of an Ikoniscope20 digital fluorescence microscope ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T17:01:43+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology","datePublished":"2022-06-22T17:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/"},"wordCount":371,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/","url":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/","name":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-06-22T17:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ikonisys-announces-the-first-sale-of-the-ikoniscope20-solution-including-the-newly-added-reagents-to-comprehensive-urology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45378"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45378\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}